RECURRENT ORAL CANCER: CURRENT AND EMERGING THERAPEUTIC APPROACHES
Oral cancer cavity (OCC) is associated with high incidence of loco-regional recurrences, which account for the majority of treatment failures post-surgery and radiotherapy. The time-course of relapse manifestation and metastasis are unpredictable. Relapsed OCC represents a major clinical challenge i...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2012-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2012.00149/full |
| _version_ | 1819021055574933504 |
|---|---|
| author | Sabrina Daniela Silva Sabrina Daniela Silva Michael eHier Alex eMlynarek Luiz Paulo Kowalski Moulay A. eAlaoui-Jamali |
| author_facet | Sabrina Daniela Silva Sabrina Daniela Silva Michael eHier Alex eMlynarek Luiz Paulo Kowalski Moulay A. eAlaoui-Jamali |
| author_sort | Sabrina Daniela Silva |
| collection | DOAJ |
| description | Oral cancer cavity (OCC) is associated with high incidence of loco-regional recurrences, which account for the majority of treatment failures post-surgery and radiotherapy. The time-course of relapse manifestation and metastasis are unpredictable. Relapsed OCC represents a major clinical challenge in part due to their aggressive and invasive behaviors. Chemotherapy remains the only option for advanced OCC whenever salvage surgery or re-irradiation is not feasible, but its efficacy is limited as a result of the drug resistance development. Alternatives to use of different permutations of standard cytotoxic drugs or combinations with modulators of drug resistance have led to incremental therapeutic benefits. The introduction of targeted agents and biologics against selective targets that drive cancer progression has opened-up optimism to achieve superior therapeutic activity and overcome drug resistance because, unlike the non-selective cytotoxic, the target can be monitored at molecular levels to identify patients who can benefit from the drug. This review discusses the multifactorial aspects of clinical drug resistance and emerging therapeutic approaches in recurrent OCC, emphasizing recent advances in targeted therapies, immunotherapy, and potential relevance of new concepts such as epithelial-mesenchymal transition and cancer stem cell hypothesis to drug resistance. |
| first_indexed | 2024-12-21T04:01:01Z |
| format | Article |
| id | doaj.art-ef05ee9834e0408d8cf8956ef84ec197 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-21T04:01:01Z |
| publishDate | 2012-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-ef05ee9834e0408d8cf8956ef84ec1972022-12-21T19:16:44ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122012-07-01310.3389/fphar.2012.0014931446RECURRENT ORAL CANCER: CURRENT AND EMERGING THERAPEUTIC APPROACHESSabrina Daniela Silva0Sabrina Daniela Silva1Michael eHier2Alex eMlynarek3Luiz Paulo Kowalski4Moulay A. eAlaoui-Jamali5Sir Mortimer B. Davis-Jewish General HospitalMcGill UniversityMcGill UniversityMcGill UniversityAC Camargo HospitalSir Mortimer B. Davis-Jewish General HospitalOral cancer cavity (OCC) is associated with high incidence of loco-regional recurrences, which account for the majority of treatment failures post-surgery and radiotherapy. The time-course of relapse manifestation and metastasis are unpredictable. Relapsed OCC represents a major clinical challenge in part due to their aggressive and invasive behaviors. Chemotherapy remains the only option for advanced OCC whenever salvage surgery or re-irradiation is not feasible, but its efficacy is limited as a result of the drug resistance development. Alternatives to use of different permutations of standard cytotoxic drugs or combinations with modulators of drug resistance have led to incremental therapeutic benefits. The introduction of targeted agents and biologics against selective targets that drive cancer progression has opened-up optimism to achieve superior therapeutic activity and overcome drug resistance because, unlike the non-selective cytotoxic, the target can be monitored at molecular levels to identify patients who can benefit from the drug. This review discusses the multifactorial aspects of clinical drug resistance and emerging therapeutic approaches in recurrent OCC, emphasizing recent advances in targeted therapies, immunotherapy, and potential relevance of new concepts such as epithelial-mesenchymal transition and cancer stem cell hypothesis to drug resistance.http://journal.frontiersin.org/Journal/10.3389/fphar.2012.00149/fullDrug ResistanceRecurrenceoral cancerrelapsesnovel therapeutics |
| spellingShingle | Sabrina Daniela Silva Sabrina Daniela Silva Michael eHier Alex eMlynarek Luiz Paulo Kowalski Moulay A. eAlaoui-Jamali RECURRENT ORAL CANCER: CURRENT AND EMERGING THERAPEUTIC APPROACHES Frontiers in Pharmacology Drug Resistance Recurrence oral cancer relapses novel therapeutics |
| title | RECURRENT ORAL CANCER: CURRENT AND EMERGING THERAPEUTIC APPROACHES |
| title_full | RECURRENT ORAL CANCER: CURRENT AND EMERGING THERAPEUTIC APPROACHES |
| title_fullStr | RECURRENT ORAL CANCER: CURRENT AND EMERGING THERAPEUTIC APPROACHES |
| title_full_unstemmed | RECURRENT ORAL CANCER: CURRENT AND EMERGING THERAPEUTIC APPROACHES |
| title_short | RECURRENT ORAL CANCER: CURRENT AND EMERGING THERAPEUTIC APPROACHES |
| title_sort | recurrent oral cancer current and emerging therapeutic approaches |
| topic | Drug Resistance Recurrence oral cancer relapses novel therapeutics |
| url | http://journal.frontiersin.org/Journal/10.3389/fphar.2012.00149/full |
| work_keys_str_mv | AT sabrinadanielasilva recurrentoralcancercurrentandemergingtherapeuticapproaches AT sabrinadanielasilva recurrentoralcancercurrentandemergingtherapeuticapproaches AT michaelehier recurrentoralcancercurrentandemergingtherapeuticapproaches AT alexemlynarek recurrentoralcancercurrentandemergingtherapeuticapproaches AT luizpaulokowalski recurrentoralcancercurrentandemergingtherapeuticapproaches AT moulayaealaouijamali recurrentoralcancercurrentandemergingtherapeuticapproaches |